Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label,
Benefits & Risks of Treatment | Metastatic Colorectal Cancer (mCRC)| Avastin® (bevacizumab)
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
Xeloda – Treatment for Metastatic Colorectal Cancer - Clinical Trials Arena
Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma | Semantic Scholar
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Capecitabine (Xeloda) for Colon Cancer | ChemoExperts
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Cancers | Free Full-Text | Adjuvant Chemotherapy for Stage III Colon Cancer
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial - Chen - 2018 -
Colorectal Cancer – Treatments | Gastrointestinal Cancer
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
1175-Colorectal metastatic capecitabine and beVACizumab | eviQ
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer
Avastin® (bevacizumab) Dosing | MCRC Treatment
PPT - Background PowerPoint Presentation, free download - ID:2215849
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook - Cancer Treatment Reviews
Xeloda – Treatment for Metastatic Colorectal Cancer - Clinical Trials Arena
Use of Bevacizumab in the Maintenance Setting for Patients with Metastatic Colorectal Cancer (mCRC) | Research To Practice
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
